ABC	ATP binding cassette
ADC	antibody-drug conjugate
ADCC	antibody dependent cell cytotoxicity
AI	aromatase inhibitor
AIB1	amplified in breast cancer 1
ALND	axillary lymph node dissection
AR	androgen receptor
ATM	ataxia-telangiesctasia mutated
BC	breast cancer
BCRP	breast cancer resistant protein
BRCA	breast cancer gene
BsAb	bispecific antibody
CBR	clinical benefice rate
CDK4/6	cyclin-dependent kinase
CR	clinical response
CSC	cancer stem cell
CTLA4	cytotoxic T lymphocyte-associated protein 4
DDFS	distant disease-free survival
DFS	disease-free survival
DLT	dose-limiting toxicities
DoCB	duration of clinical benefit
DoR	duration of response
EGF	epidermal growth factor
EGFR	epidermal growth factor receptor
ER	estrogen receptor
FDA	food and drug administration
gBRCAm	germline BRCA mutation
HB-EGF	heparin-binding EGF-like growth factor
HER2	human epidermal growth factor receptor 2
HGF	hepatocyte growth factor
HIF1-α	hypoxia-inducible factor 1 alpha
HR	hormone receptor
HR	hazard ratio
IAES	incidence of adverse events
IDFS	invasive disease-free survival
iEFS	invasive events-free survival
IGF-1	insulin growth factor 1
IGF-1R	insulin growth factor receptor 1
MAP	microtubule associated protein
MAPK	mitogen activated protein kinase
MBC	metastatic breast cancer
MTD	maximum tolerated dose
mTOR	mammalian target of rapamycin
NAC	neoadjuvant chemotherapy
ORR	overall response rate
OS	overall survival
PARP	poly-(ADP-ribose) polymerase protein
PARPi	poly-(ADP-ribose) polymerase protein inhibitor
pCR	predicted complete response
PD-1	programmed cell death protein receptor
PDL-1	programmed cell death protein ligand
PFS	progression-free survival
PI3K	phosphoinositide 3-kinase
PPV	personalized peptide vaccine
PR	progesterone receptor
PR	partial response
PTEN	phosphatase and tensin homolog
Ras-ERK	extracellular-signal-regulated kinase
RFS	recurrence-free survival
SD	stable disease
SERD	selective estrogen receptor degrader
SERM	selective estrogen receptor modulator
SLNB	sentinel lymph mode biopsy
STnKLH	sialyl-TN keyhole limpet hemocyanin
T-DM1	trastuzumab-emtansine
TKI	tyrosine kinase inhibitor
TNBC	triple-negative breast cancer
Trop2	trophoblast antigen 2
TTF	time to treatment failure
TTP	time to treatment progression
TTR	time to treatment response
VEGF	vascular endothelial growth factor